Cetuximab (Erbitux)
Sponsors
Per Pfeiffer, Shandong Cancer Hospital and Institute, University Hospital, Ghent, Bayer, Groupe Oncologie Radiotherapie Tete et Cou
Conditions
CRCCancerColorectal Liver Metastasis (CRLM)Esophageal CancerMetastatic Colorectal CancerNeoplasmsRecurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Phase 1
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
CompletedNCT01973868
Start: 2013-11-21End: 2018-04-03Updated: 2019-04-09
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
RecruitingNCT07204574
Start: 2025-05-14End: 2025-12-31Target: 40Updated: 2025-10-02
Phase 2
FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor
CompletedNCT00660582
Start: 2008-04-30End: 2013-02-28Updated: 2015-01-21
Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma
CompletedNCT00815308
Start: 2009-01-31End: 2010-07-31Updated: 2011-02-08
A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.
CompletedNCT00996567
Start: 2009-10-31End: 2015-09-30Updated: 2017-02-09
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
RecruitingNCT06640725
Start: 2025-01-02End: 2028-12-02Target: 70Updated: 2025-01-15
FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis
RecruitingNCT06988852
Start: 2023-05-01End: 2030-12-31Target: 300Updated: 2025-05-25